CClinicalTrials.gg
Status unknownNCT00868270Updated Mar 24, 2009

Urinary Cytokine Levels as a Prognostic Marker for Kidney Scarring After Pyelonephritis

An observational study in Kidney Scarring Post-Febrile UTI, sponsored by Hillel Yaffe Medical Center. Status unknown at 1 site in Israel. Open to participants aged Up to 7 Years. Per ClinicalTrials.gov, last updated 2009-03-24.

Sponsored by Hillel Yaffe Medical Center · Observational

The sponsor has not verified this record recently (last verified Mar 2009), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
Up to 7 Years
Sex
All
01

Study summary

The prevalence of kidney scarring after UTI is approximately 5-57%. UTIs are caused mainly by bacteria that cause local and systemic immunological reaction that are accompanied by cytokines. These cytokines are a main factor in the inflammatory process. They are produced by leukocytes, macrophages, fibroblasts, endothelial cells and epithelial cells in the kidney tissue. Interleukin 6 and 8 (IL-6 IL-8) were found in high levels in the urine of children and adults who suffer from UTIs. Other studies on animals have found a relationship between inflammatory reaction and scarring in the kidney. We hypothesize that we will find a similar relationship between the level of IL-6, IL-8 in the urine during acute pyelonephritis in children and the probability of kidney scarring.

02

Conditions studied

  • Kidney Scarring Post-Febrile UTI
03

In context

Glomerulonephritis

149 studies on the registry are indexed under Glomerulonephritis; 38 are open to participants now.

This study's planned enrollment of 35 is below the median of 100 across 34 observational studies indexed under Glomerulonephritis.

Browse Glomerulonephritis studies →

Lead sponsor

Hillel Yaffe Medical Center is the lead sponsor of 301 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Hospitalized children with UTIs

Inclusion criteria

  • Children aged 0-7
  • First episode febrile UTI

Exclusion criteria

Exclusion Criteria:

  • Recurrent UTI
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)

Groups and cohorts

  • Children with UTIs
06

What researchers measure

Primary outcomes

  1. High prevalence of kidney scarring in children with high levels of urine interleukins

    Time frame: six months

07

Study locations

1 site
  • Hillel Yaffe Medical Center
    Hadera, 38100, Israel
    • Hassan Jassar, MD · Contact
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00868270
Lead sponsor
Hillel Yaffe Medical Center
First posted
Mar 24, 2009
Start date
May 2009
Last update
Mar 24, 2009

Study contacts

Hassan Jassar, MD
Contact
hasjassar@hotmail.com
972-4-630-4332
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion